Behavioral Health

Somatic symptom disorder and illness anxiety

Clinical Overview and When to Suspect Somatic Symptom and Illness Anxiety Disorders

— SSD: ≥1 somatic symptom that is distressing or disruptive, plus excessive thoughts/feelings/behaviors (disproportionate health concerns, persistent anxiety, excessive time/energy), for >6 months.

— IAD: preoccupation with having/acquiring a serious illness with somatic symptoms that are absent or only mild; high health anxiety, excessive checking or avoidance, ≥6 months.

— Patient with multiple unexplained symptoms across organ systems, multiple providers, repeated negative workups ("doctor shopping").

— Disproportionate distress about a normal sensation (e.g., interpreting a tension headache as a brain tumor).

— High utilization: frequent ED visits, online symptom searching, repeated reassurance-seeking that fails to relieve anxiety.

— In ambulatory care, a thick chart, normal recent imaging, and a chief complaint of "I know something is wrong" should trigger active screening.

— SSD prevalence ~5–7% in general population; F > M.

— Onset typically before age 30; chronic, relapsing course.

— Strong comorbidity with depression, anxiety, PTSD, and personality disorders.

Somatic symptom disorder (SSD) and illness anxiety disorder (IAD) are DSM-5 disorders defined by distress and dysfunction centered on bodily symptoms or fear of disease, regardless of whether a medical explanation exists.

When to suspect on Step 3:

Epidemiology highlights:

Key distinction: SSD focuses on the symptom itself ("this pain is unbearable, no one can fix it"); IAD focuses on the diagnosis ("I have cancer even though tests are negative"). Both differ from factitious disorder (intentional production of symptoms for sick role) and malingering (intentional production for external gain).

Step 3 management anchor: the diagnosis is inclusive, not exclusive — you do NOT need to fully rule out organic disease before naming SSD/IAD; coexisting medical illness is allowed and common.

Presentation Patterns and Key History

— Middle-aged woman with years of fatigue, abdominal pain, pelvic pain, headaches, dizziness, palpitations, each evaluated extensively with normal results.

— Symptom descriptions are vivid, catastrophic, and emotionally charged ("the worst pain anyone has ever had").

— Patient resists psychiatric framing: "It's not in my head."

— Younger or middle-aged adult who scrutinizes body sensations (heartbeat, moles, lymph nodes), repeatedly checks vitals, consults Dr. Google.

— Two subtypes:

— Care-seeking type: frequent visits, demands for tests.

— Care-avoidant type: avoids doctors entirely out of fear of bad news — easy to miss.

— Symptom timeline and stressors (job loss, abuse history, recent illness in a relative).

— PHQ-9 and GAD-7 — comorbid depression/anxiety in >50%.

— Trauma history, especially childhood abuse and ACEs — strong association with SSD.

— Functional impact: missed work, school, relationships, finances.

— Substance use, especially benzodiazepines and opioids prescribed by multiple providers.

— Prior workups: gather records to avoid redundant testing.

— Objective findings: weight loss, fever, melena, focal neuro deficits, new lymphadenopathy.

— Age >50 with new somatic complaints (lower base rate of primary somatoform).

— Nocturnal symptoms that wake from sleep.

Classic SSD presentation:

Classic IAD presentation:

Targeted history elements:

Red flags that argue AGAINST pure SSD/IAD (warrant continued workup):

Board pearl: In SSD, the diagnosis hinges on the patient's response to symptoms (excessive thoughts/behaviors/time), not on whether a medical explanation is found. A patient with documented IBS who spends hours daily worrying about cancer despite normal colonoscopy can still meet SSD criteria.

Step 3 management: Use a single primary care home with scheduled (not symptom-triggered) visits — this is the highest-yield longitudinal intervention.

Physical Exam Findings and Functional Assessment

— Perform a focused but thorough exam at each visit; brief, structured, predictable.

— Document objective findings carefully — normal exams reassure both clinician and (less reliably) patient.

— Avoid hostile or dismissive language ("there's nothing wrong with you") — this escalates symptom focus.

— Vital signs typically normal; mild tachycardia from anxiety.

— Tender points without inflammation; diffuse, inconsistent tenderness.

— Distractibility of pain (pain disappears when attention diverted) — suggestive but not diagnostic.

— Normal neuro exam despite reported weakness/numbness; give-way weakness, Hoover sign positive in functional weakness (overlapping with functional neurologic disorder).

— Work, school, ADLs/IADLs, sleep, sexual function, social engagement.

— Number of healthcare encounters in past 12 months.

— Polypharmacy review — particularly opioids, benzodiazepines, gabapentinoids, PPIs, stimulants.

— PHQ-15 (somatic symptom severity), SSS-8, Whiteley Index (health anxiety).

— Co-administer PHQ-9, GAD-7, PC-PTSD-5.

Somatoform disorders have no pathognomonic exam findings — the exam is performed to build trust, validate the patient, and screen for organic disease, not to "catch" them.

General approach:

Common findings:

Functional assessment is the real "exam":

Screening tools:

Key distinction: Functional neurologic disorder (conversion) presents with neurologic exam findings incompatible with disease (e.g., Hoover sign, tremor entrainment, tubular vision) — it is a rule-in diagnosis based on positive signs, not a rule-out.

Board pearl: A normal exam in a high-utilizer patient is a therapeutic finding — share it concretely: "Your abdomen is soft, no masses, bowel sounds normal." Concrete normal findings reduce anxiety more than vague reassurance.

Diagnostic Workup — Initial Labs, Imaging, and Stewardship

— CBC, CMP, TSH (thyroid disease mimics countless somatic complaints).

— HbA1c if neuropathic or fatigue symptoms.

— Vitamin B12, vitamin D if fatigue/neuropathy.

— Urinalysis for GU symptoms; pregnancy test in reproductive-age women before imaging/meds.

— HIV, RPR if risk factors and protean symptoms.

— ESR/CRP if inflammatory pattern suspected (but nonspecific).

— Order only when clinically indicated — incidentalomas in somatoform patients fuel further anxiety and testing cascades.

— Document the specific clinical question each test answers.

— Repeating prior negative workups to placate the patient — reinforces illness behavior and exposes to radiation, false positives, and procedural complications.

— Ordering broad autoimmune panels (ANA, RF) without specific findings — high false-positive rate amplifies somatic preoccupation.

— "Just to be safe" CT scans — VOMIT (victim of modern imaging technology) phenomenon.

— "I've reviewed your prior workup. Another CT won't give us new information and could expose you to radiation. Let's focus on what we CAN improve — your sleep, function, and pain coping."

Step 3 emphasizes judicious, hypothesis-driven testing — not blanket workups.

Baseline labs reasonable in a new somatic complaint workup:

Imaging:

What NOT to do:

Communication framing when declining a test:

Step 3 management: Establish a single PCP, scheduled visits every 4–6 weeks regardless of symptoms, brief focused exam each visit, avoid PRN testing, and explicitly link emotional stressors to symptom flares over time.

Board pearl: The correct answer to "What's the next step?" in a stable high-utilizer with negative prior workup and new vague complaint is almost always scheduled follow-up with the PCP, NOT another scan or specialist referral.

Key distinction: SSD/IAD diagnosis does not require exhaustive medical workup — over-testing harms the patient and the diagnosis itself.

Diagnostic Workup — Confirming the Psychiatric Diagnosis

— A. ≥1 somatic symptom that is distressing or disruptive.

— B. Excessive thoughts, feelings, or behaviors related to the symptom, manifested by ≥1 of:

— Disproportionate, persistent thoughts about seriousness.

— Persistently high anxiety about health/symptoms.

— Excessive time/energy devoted to symptoms or health.

— C. State of being symptomatic is persistent (>6 months), though specific symptoms may change.

— Specifiers: with predominant pain, persistent, severity mild/moderate/severe.

— A. Preoccupation with having or acquiring a serious illness.

— B. Somatic symptoms absent or mild; if another medical condition exists, preoccupation is clearly excessive.

— C. High anxiety about health; alarmed easily.

— D. Excessive health-related behaviors (checking) or maladaptive avoidance.

— E. ≥6 months (specific feared illness may change).

— F. Not better explained by another mental disorder.

— Specify care-seeking vs care-avoidant.

— If somatic symptoms are prominent → SSD.

— If symptoms are minimal but fear of disease dominates → IAD.

— Major depression, GAD, panic disorder, OCD, PTSD.

— Substance use disorders (especially iatrogenic opioid/benzo use).

— Personality disorders, particularly borderline and dependent.

— Factitious disorder: intentional symptom production for the sick role (no external reward).

— Malingering: intentional production for external gain (disability, opioids, time off work) — not a mental disorder, not in DSM Axis-equivalent categories.

— SSD/IAD symptoms are NOT intentionally produced — the distress is genuine.

DSM-5 criteria — SSD:

DSM-5 criteria — IAD:

Differentiating tools:

Comorbid screening (mandatory):

Board pearl: The 6-month duration criterion separates SSD/IAD from acute adjustment reactions or transient health anxiety triggered by a recent diagnosis in self or family.

Key distinction:

First-Line Management Logic and Therapeutic Framework

— One primary clinician as gatekeeper — minimizes fragmented care and contradictory workups.

— Regularly scheduled brief visits (every 4–6 weeks), not symptom-driven.

— Acknowledge symptoms as real — never tell the patient "it's all in your head."

— Shift goals from cure → function: improve sleep, work, relationships, mood.

— Limit unnecessary tests, referrals, hospitalizations, and medications.

— Screen and treat comorbid depression/anxiety aggressively.

— Cognitive-behavioral therapy (CBT) has the strongest evidence for both SSD and IAD.

— Targets catastrophic interpretations of bodily sensations, safety behaviors, and avoidance.

— Mindfulness-based therapy and acceptance and commitment therapy (ACT) also effective.

— Brief psychodynamic therapy in select patients with trauma history.

— Validate: "I believe your symptoms are real and distressing."

— Reframe: "Stress and the body are deeply connected — addressing both gives the best results."

— Set expectations: "We may not eliminate symptoms entirely, but we can improve how much they interfere with your life."

— Premature reassurance ("everything is fine") — fails because patient anxiety is the problem, not the data.

— Confrontation about psychological origin in early visits.

— Promising a cure.

— 1) Establish PCP as point of contact.

— 2) Schedule monthly visits.

— 3) Refer to CBT therapist.

— 4) Treat comorbid depression/anxiety with SSRI.

— 5) Reconcile and deprescribe opioids/benzos.

Core principles (high-yield Step 3 framework):

First-line treatment modality: psychotherapy

Pharmacotherapy: adjunctive; primarily for comorbid depression/anxiety (see chunk 7).

Patient communication scripts:

What to avoid:

Step 3 management sequence for newly diagnosed SSD in clinic:

Board pearl: The single most consistently correct answer for SSD management on boards is "regular scheduled visits with a single primary care provider" — this both treats the disorder and prevents iatrogenic harm.

Pharmacotherapy — First-Line Regimens

— Sertraline 25–50 mg daily, titrate to 100–200 mg.

— Fluoxetine 20–60 mg, escitalopram 10–20 mg, paroxetine (more anticholinergic — avoid in elderly).

— Helpful when depression, GAD, panic, or OCD-spectrum health anxiety are present.

— Allow 6–8 weeks at therapeutic dose to judge response.

— Start low and go slow — somatoform patients are exquisitely sensitive to side effects and often discontinue early; warn about transient nausea, jitteriness, headache.

— Duloxetine 30–60 mg — particularly useful in SSD with predominant pain (fibromyalgia, diabetic neuropathy, chronic musculoskeletal pain).

— Venlafaxine XR — watch BP.

— Benzodiazepines — reinforce avoidance, addiction risk, falls; rarely indicated.

— Opioids — no role in chronic somatoform pain; risk of OUD, hyperalgesia.

— Gabapentin/pregabalin — limited evidence outside specific neuropathic pain; misuse potential.

— Stimulants for "brain fog" — not indicated.

— Polypharmacy — each new med adds side effects that become new symptoms.

— Inventory all meds and supplements at each visit.

— Taper opioids and benzos slowly (10% per 1–4 weeks) with behavioral support.

— Replace with SSRI + CBT + scheduled visits.

No FDA-approved medication exists specifically for SSD or IAD. Pharmacotherapy targets comorbid conditions and certain symptom domains.

First-line: SSRIs

Second-line / specific indications: SNRIs

TCAs (low dose) — amitriptyline 10–25 mg qhs for chronic pain syndromes, functional GI symptoms, headaches; mind anticholinergic load and cardiac effects.

What to AVOID:

Deprescribing strategy:

Step 3 management: For SSD with predominant pain + depression, duloxetine is often the highest-yield single agent — treats both domains.

Board pearl: When a stem describes a patient with SSD asking for "something stronger" after multiple analgesics failed, the answer is NOT another medication — it's CBT referral and scheduled follow-up.

Expanded Pharmacology and Non-Pharmacologic Modalities

— CBT (12–16 sessions typical):

— Cognitive restructuring of catastrophic illness beliefs.

— Behavioral experiments (e.g., reducing checking, exposure to feared sensations).

— Activity scheduling and graded exercise.

— Exposure and response prevention (ERP) — for IAD with checking/reassurance-seeking behaviors (overlap with OCD spectrum).

— Mindfulness-based stress reduction (MBSR) — 8-week structured program.

— Acceptance and commitment therapy (ACT) — accept symptoms, commit to value-driven action.

— Group therapy — reduces isolation, normalizes experience.

— Aerobic exercise — 150 min/week moderate intensity; reduces somatic symptom burden and depression.

— Sleep hygiene and CBT-I for comorbid insomnia.

— Physical therapy with graded activity — for functional pain and deconditioning.

— Biofeedback for tension headache, functional GI symptoms.

— Functional GI (IBS overlap): low-dose TCA or SSRI; consider rifaximin/dietary trials only with GI confirmation.

— Fibromyalgia overlap: duloxetine, milnacipran, pregabalin (FDA-approved), plus exercise.

— Chronic tension headache: amitriptyline.

— Health anxiety (IAD): SSRI + CBT/ERP; sertraline and fluoxetine best evidence.

— Collaborative care model — PCP + behavioral health consultant + psychiatrist consultant; level-1 evidence for improving outcomes in somatic and depressive disorders.

— Involve family to reduce reinforcement of sick-role behaviors and reassurance loops.

Psychotherapy modalities (highest-yield, expanded):

Adjunctive non-pharm:

Pharmacotherapy by symptom cluster:

Care coordination:

CCS pearl: In an inpatient CCS for a high-utilizer admitted for chest pain with negative cardiac workup, after ruling out ACS, the correct sequence is: psychiatric consultation, social work, schedule outpatient PCP follow-up within 1–2 weeks, deprescribe inappropriate analgesics, avoid additional ED-driven imaging, and discharge with explicit single-provider plan.

Board pearl: CBT + SSRI + scheduled PCP visits beats any single modality alone.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher base-rate of real organic disease — threshold for workup is lower; do not anchor on prior SSD diagnosis.

— New somatic complaints after age 50 warrant fresh evaluation, especially weight loss, GI bleeding, neuro deficits.

— Depression frequently presents somatically in older adults — screen with Geriatric Depression Scale.

— Cognitive impairment may amplify health anxiety; screen with MoCA.

— Preferred SSRIs: sertraline, escitalopram (fewer interactions, cleaner profile).

— Avoid paroxetine (anticholinergic, Beers criteria).

— Avoid TCAs at antidepressant doses; if used for pain, nortriptyline preferred over amitriptyline.

— Avoid benzodiazepines — fall risk, delirium, cognitive impairment.

— Watch for SIADH/hyponatremia with SSRIs — check sodium at 2–4 weeks, especially in patients on diuretics.

— Monitor QT interval: citalopram limited to 20 mg/day if >60 yo.

— Most SSRIs need minor adjustment; paroxetine and citalopram require dose reduction in CrCl <30.

— Duloxetine: avoid if CrCl <30.

— Venlafaxine: reduce dose 25–50% in significant renal impairment.

— Gabapentin/pregabalin (if used): aggressive renal dose adjustment.

— Duloxetine: contraindicated in chronic liver disease and in heavy alcohol use.

— TCAs: reduce dose, prolonged half-life.

— Sertraline often preferred in mild–moderate liver dysfunction.

Elderly considerations:

Medication choices in elderly:

Renal impairment:

Hepatic impairment:

Step 3 management: In an 80-year-old with chronic SSD presenting with new weight loss and night sweats, the answer is age-appropriate cancer workup, not reassurance — somatoform diagnoses do not immunize against new disease.

Board pearl: Late-life "somatization" is often underlying depression — treating the depression (with SSRI + therapy) frequently resolves the somatic complaints.

Key distinction: Anchoring bias is the dominant patient-safety error in somatoform patients — every new symptom deserves fresh evaluation calibrated to risk.

Special Populations — Pregnancy, Pediatrics, and Cultural Considerations

— Untreated maternal anxiety/depression carries risks (preterm birth, low birth weight, poor attachment) — do not undertreat.

— SSRIs in pregnancy:

— Sertraline is generally preferred (lowest placental transfer, robust safety data).

— Avoid paroxetine — associated with cardiac defects (Ebstein anomaly risk debated but conventionally avoided).

— Counsel about neonatal adaptation syndrome (jitteriness, feeding difficulty) and small risk of persistent pulmonary hypertension of the newborn.

— CBT is first-line when severity allows — no fetal risk.

— Avoid benzodiazepines (cleft palate concerns in 1st trimester, neonatal withdrawal).

— Distinguish IAD-driven infant health checking from postpartum OCD (intrusive thoughts about harm) and postpartum depression.

— Children somatize via recurrent abdominal pain, headaches, limb pain, fatigue, dizziness.

— Often linked to school avoidance, bullying, family stress, abuse.

— Evaluate parental health anxiety — "by proxy" reinforcement common.

— Treatment: family-based CBT, return to school as therapeutic goal, school nurse involvement, scheduled pediatrician visits.

— Avoid medicalization; fluoxetine has best pediatric SSRI data if pharmacotherapy needed.

— Somatic idioms of distress vary by culture (e.g., "nervios," "shenjing shuairuo," "hwa-byung").

— Stigma around mental illness in many cultures makes somatic framing more acceptable — work within the patient's framework rather than forcing psychiatric labeling.

— Use trained medical interpreters; family members can introduce bias and miss psychiatric nuance.

Pregnancy:

Postpartum:

Pediatrics and adolescents:

Cultural considerations:

Board pearl: Adolescent with recurrent abdominal pain, normal workup, missing >20 school days/year → return to school is itself the treatment, supported by family CBT.

Step 3 management: In pregnancy with moderate SSD, start with CBT; add sertraline if CBT alone inadequate; document shared decision-making about risks/benefits.

Complications and Adverse Outcomes

— Radiation exposure from repeated CT scans → lifetime cancer risk.

— Procedural complications: bleeding, infection, perforation from unnecessary endoscopies, biopsies, surgeries.

— Surgical scars and adhesions from "exploratory" procedures.

— Polypharmacy: drug interactions, anticholinergic burden, falls.

— Opioid use disorder and overdose — somatoform pain patients are a high-risk OUD population when chronically prescribed.

— Benzodiazepine dependence, cognitive impairment, falls, MVAs.

— Incidentalomas triggering further testing cascades.

— Occupational disability, unemployment, dependent sick role.

— Relationship strain; family burnout; secondary gain dynamics reinforcing illness.

— Social isolation, financial hardship.

— Suicide risk elevated, particularly with comorbid depression and chronic pain — screen at every visit.

— High utilization → ED visits, hospital admissions, specialist referrals; costly and disruptive.

— Provider burnout and countertransference — leads to dismissive care and missed real diagnoses.

— SSD does not exclude concurrent disease; ~25–50% develop or have comorbid medical illness.

— Common misses: thyroid disease, autoimmune disease (SLE, MS), early malignancy, sleep apnea, celiac disease, B12 deficiency, paraneoplastic syndromes.

— Treat each new objective finding on its own merits.

— Use objective criteria (weight loss, lab abnormalities, exam findings, imaging) — not symptom intensity alone.

— Avoid both over- and under-investigation; document reasoning.

Iatrogenic complications (the dominant harm category):

Psychosocial complications:

Healthcare system complications:

Missed organic diagnoses (anchoring bias):

Step 3 management of suspected new organic disease in a known SSD patient:

Board pearl: The two competing errors in SSD are over-testing (iatrogenic harm) and under-testing (missed disease) — defense against both is structured longitudinal care with one PCP.

Key distinction: A patient with SSD who develops new objective findings deserves a full workup, period — never reflexively attribute new findings to the somatoform diagnosis.

When to Escalate Care — Psychiatry, ED, and Inpatient Triage

— Diagnostic uncertainty between SSD, IAD, factitious disorder, OCD, or psychotic disorder with somatic delusions.

— Failure of first-line SSRI + CBT after 3–6 months.

— Severe functional impairment (unable to work, housebound).

— Comorbid severe depression, PTSD, personality disorder.

— Polypharmacy needing complex medication management.

— Active suicidal ideation with plan/intent — emergency evaluation; consider involuntary hold if criteria met.

— Severe self-neglect from health anxiety (e.g., refusing to eat for fear of poisoning — overlaps with delusional disorder, somatic type).

— Acute psychiatric decompensation, psychosis.

— Hospitalize for objective, identified medical needs only.

— Avoid admission to "rule out" repeatedly negative concerns — reinforces illness behavior.

— When unavoidable, set clear length-of-stay expectations and a defined workup list at admission; involve psychiatry early.

— Develop a care plan in the chart: known diagnoses, baseline labs/imaging, preferred PCP, what NOT to repeat.

— Address acute new findings; avoid blanket retesting.

— Provide warm handoff to PCP within 1–2 weeks.

— Refer to specialists with a specific clinical question, not "please evaluate."

— Communicate the SSD/IAD diagnosis to specialists so they can co-manage rather than re-test.

Outpatient psychiatry referral indications:

Emergency/inpatient psychiatric escalation:

Medical hospitalization indications (the harder call):

ED management of frequent flyers:

Specialist consultation principles:

CCS pearl: For SSD patient admitted with chest pain and negative ACS workup, key orders include: telemetry until ACS ruled out, psychiatry consult, social work, PCP appointment within 1–2 weeks, smoking cessation/depression screening, discharge with no new opioids, and medication reconciliation to deprescribe inappropriate agents.

Board pearl: "Admit for further workup" is almost never the right answer in a stable SSD patient with normal vitals and negative initial evaluation — outpatient follow-up is.

Key Differentials — Other Somatoform and Related Disorders

— Neurologic symptoms (weakness, sensory loss, seizures, tremor) with positive signs of incompatibility (Hoover sign, tremor entrainment, dissociative seizures with preserved awareness).

— Diagnosed by positive rule-in features, not exclusion.

— Intentional production or feigning of physical/psychological signs (e.g., self-injecting insulin, contaminating urine samples).

— Motivation: assume sick role (no external incentive).

— Factitious disorder imposed on another (formerly Munchausen by proxy) — child abuse; mandatory reporting.

— Intentional production for external gain (money, drugs, disability, avoiding work/jail).

— Suspect with inconsistency between claimed disability and observed function, medicolegal context, lack of cooperation with evaluation.

— Preoccupation with perceived physical defect in appearance, not illness — categorized with OCD spectrum.

— Overlapping with IAD; characterized by ego-dystonic intrusive thoughts and compulsive behaviors. ERP is treatment.

— Episodic somatic symptoms (palpitations, dyspnea, chest pain) with discrete attacks and anticipatory anxiety; distinct from chronic somatic preoccupation.

— Broad worry across multiple domains, including health — somatic complaints common but not the focal feature.

— Fatigue, pain, GI symptoms can dominate; anhedonia and low mood present.

— Intentional + external gain → malingering.

— Intentional + sick role → factitious.

— Not intentional + many symptoms + excessive response → SSD.

— Not intentional + fear of disease + minimal symptoms → IAD.

— Not intentional + neurologic + positive incompatibility signs → FND.

Functional neurologic disorder (conversion disorder):

Illness anxiety disorder (IAD): minimal somatic symptoms, dominant fear of disease.

Somatic symptom disorder (SSD): prominent somatic symptoms with disproportionate response.

Factitious disorder:

Malingering (NOT a mental disorder):

Body dysmorphic disorder:

OCD with health-related obsessions:

Panic disorder:

Generalized anxiety disorder:

Depression with somatic features:

Key distinction tree:

Board pearl: A "tell" for factitious disorder is healthcare worker patient, multiple hospitals, eager for procedures, evasive history.

Key Differentials — Medical/Organic Mimics to Exclude

— Hyperthyroidism: anxiety, palpitations, weight loss, tremor → check TSH.

— Hypothyroidism: fatigue, weight gain, depression, constipation, cold intolerance → TSH.

— Pheochromocytoma: episodic headache, palpitations, sweating, hypertension → plasma/urine metanephrines.

— Carcinoid: flushing, diarrhea, wheezing → 24-h urine 5-HIAA.

— Cushing/Addison: weight, mood, fatigue changes.

— Hyperparathyroidism: "bones, stones, abdominal groans, psychiatric overtones."

— SLE: arthralgia, rash, fatigue, neuropsychiatric symptoms → ANA, complement.

— Multiple sclerosis: episodic neurologic symptoms across time/space → MRI brain/spine.

— Myasthenia gravis: fatigable weakness.

— Sjögren, RA, vasculitides.

— HIV: protean symptoms, neuropsychiatric, weight loss → screen.

— Lyme in endemic areas; syphilis (great imitator).

— Migraine, temporal lobe epilepsy, narcolepsy, early Parkinson or dementia.

— Early lymphoma (B symptoms), multiple myeloma (back pain, fatigue, hypercalcemia), paraneoplastic syndromes.

— Celiac, IBD, chronic pancreatitis, porphyria (intermittent abdominal pain + neuropsychiatric).

— B12 deficiency, heavy metal toxicity (lead, mercury), carbon monoxide exposure (multiple household members with similar symptoms).

— Obstructive sleep apnea — fatigue, mood, headache, cognitive complaints.

— Arrhythmias (palpitations, syncope), POTS (dizziness, tachycardia on standing), microvascular angina.

Many medical conditions present with protean, multi-system symptoms that masquerade as somatoform — high-yield must-not-miss list:

Endocrine:

Autoimmune:

Infectious:

Neurologic:

Hematologic/Oncologic:

GI:

Metabolic/Toxic:

Sleep:

Cardiac:

Step 3 management: When a known SSD patient presents with a new symptom cluster, run a focused, rational workup based on the specific symptoms — not "everything," not "nothing."

Board pearl: TSH, CBC, CMP, HIV catch most high-yield mimics in fatigue/multi-system presentations.

Long-Term Management, Secondary Prevention, and Discharge Planning

— Identified primary care home with one continuous PCP.

— Scheduled visits every 4–6 weeks; titrate to every 2–3 months once stable.

— Brief, structured visit template: focused exam, review of function, screening (PHQ-9, GAD-7), medication reconciliation, reinforcement of coping strategies.

— Maintenance CBT booster sessions every 3–6 months.

— SSRI continuation at least 6–12 months after symptom remission; longer if recurrent.

— Annual preventive care to USPSTF standards — somatoform patients often paradoxically miss routine screening (over-tested for the wrong things, under-screened for indicated ones).

— Age-appropriate cancer screening, immunizations, lipid/diabetes screening.

— Bone health in chronic opioid/SSRI users — DEXA per guidelines.

— Cardiovascular risk management (ASCVD calculator); SSD patients have higher CV mortality partly from sedentary behavior and untreated risk factors.

— Document SMART goals: return to work, resume exercise, social engagement, sleep schedule.

— Track function with tools (WHODAS 2.0, brief disability index) — not just symptom counts.

— Medication reconciliation with deprescribing of unnecessary drugs.

— PCP appointment within 7–14 days.

— Written care plan shared with patient and PCP.

— Avoid new opioid/benzo scripts at discharge.

— Communicate diagnosis transparently to receiving providers.

— Coach family to avoid reinforcing illness behavior (excessive reassurance, taking over ADLs) while remaining empathic.

— Encourage shared activities that focus away from symptoms.

Longitudinal SSD/IAD care plan elements:

Secondary prevention of complications:

Functional restoration goals:

Discharge planning after any hospitalization:

Family/caregiver education:

Step 3 management for a stable SSD patient at 12-month follow-up doing well on sertraline + CBT: continue SSRI, space visits to every 3 months, reinforce function, screen for relapse triggers, do not abruptly stop SSRI.

Board pearl: Recurrence is common; maintaining the therapeutic relationship through stable periods is the best relapse prevention.

Follow-Up, Monitoring Parameters, and Counseling

— First 3 months after diagnosis or new medication: every 2–4 weeks.

— Stable phase: every 4–6 weeks, then 2–3 months.

— Always scheduled, never PRN-only — PRN visits reinforce symptom-contingent care.

— Function (work, social, ADLs) — primary outcome.

— PHQ-9, GAD-7 every 1–3 months.

— Symptom severity (SSS-8, PHQ-15).

— Medication side effects and adherence.

— Substance use, sleep, exercise.

— Suicide risk screening.

— At 2–4 weeks: tolerability, suicidality (especially in young adults — black box warning under 25).

— At 6–12 weeks: efficacy; titrate if inadequate response.

— Sodium at 2–4 weeks in elderly or diuretic users (SIADH risk).

— Bleeding risk with concomitant NSAIDs/anticoagulants.

— Sexual side effects — ask explicitly; common cause of non-adherence.

— Serotonin syndrome risk with triptans, tramadol, linezolid, MAOIs.

— Stress-symptom link education (mind-body model).

— Diaphragmatic breathing, progressive muscle relaxation.

— Sleep hygiene; limit caffeine and alcohol.

— Reduce health-information consumption (limit symptom Googling, health-related social media).

— Limit reassurance-seeking — explicit behavioral contract in IAD.

— Identify early warning signs (sleep loss, escalating checking, ED visits).

— Action plan: contact PCP or therapist before going to ED for non-emergent concerns.

Monitoring schedule:

At each visit, assess:

SSRI-specific monitoring:

Counseling content:

Relapse prevention plan:

Step 3 management: When tapering SSRI after 12+ months remission, decrease gradually over 4+ weeks to avoid discontinuation syndrome; monitor for relapse for 6 months off medication.

Board pearl: The single most important outcome to track is functional improvement, not symptom elimination — patients often "feel" symptoms but live full lives, which is success.

Ethical, Legal, and Patient Safety Considerations

— Patients have a right to know their diagnosis. Use the term somatic symptom disorder explicitly while validating that symptoms are real and not feigned.

— Avoid pejorative language ("functional," "psychosomatic") if it alienates the patient — collaborate on language.

— When declining a requested test, document shared decision-making, risks of unnecessary testing, and the rationale.

— When prescribing SSRIs, discuss suicidality warning in patients <25, sexual side effects, and pregnancy considerations.

— Patients with somatoform disorders generally retain capacity to make medical decisions. Refusal of treatment is not itself evidence of incapacity — assess understanding, appreciation, reasoning, and ability to communicate choice.

— Factitious disorder imposed on another (formerly Munchausen by proxy) is child abuse — mandatory CPS report. Likewise for vulnerable adults — APS report.

— Document objective findings (e.g., inconsistent histories across providers, lab evidence of induced illness) before reporting; consult hospital legal/risk management.

— High-risk transition points: ED → home, hospital → home, PCP change, insurance change.

— Mitigations: medication reconciliation, warm handoffs, shared electronic care plan flagged in chart, scheduled PCP follow-up within 7–14 days.

— Risk of opioid/benzo continuation through transitions — explicitly address in discharge orders.

— Honest assessment of functional capacity required.

— Avoid medical certification of total disability without objective basis — fuels chronic disability and worsens outcomes.

— Encourage modified duty and return-to-work plans.

— Countertransference (frustration, dismissal) is common; recognize, manage, and seek peer support rather than acting on it.

— Provider burnout is a patient safety issue — rotating teams in high-utilizer cases helps.

— Mental health diagnoses carry stigma — protect under HIPAA; involve family only with patient consent (except in emergencies).

Therapeutic honesty vs. paternalism:

Informed consent:

Capacity assessment:

Mandatory reporting:

Patient safety transitions of care:

Disability and work documentation:

Professional ethics:

Privacy:

Board pearl: Telling a patient "there's nothing wrong with you" after a normal workup is both clinically wrong and an ethical failure — it dismisses real suffering and erodes trust.

High-Yield Associations and Rapid-Fire Clinical Facts

SSD = somatic symptoms + excessive response, >6 months.

IAD = fear of disease, minimal somatic symptoms, >6 months. Two subtypes: care-seeking and care-avoidant.

DSM-5 dropped "somatization disorder," "hypochondriasis," "pain disorder," and "undifferentiated somatoform disorder" — folded into SSD and IAD.

First-line treatment: CBT for both SSD and IAD.

First-line pharmacotherapy: SSRI (sertraline, fluoxetine, escitalopram); duloxetine if pain predominant.

Avoid: opioids, benzodiazepines, polypharmacy, repeated unnecessary testing.

Best single intervention: regularly scheduled visits with one PCP.

Female:male ratio: ~10:1 historical for somatization; closer to 2:1 for SSD; IAD roughly equal.

Onset: typically before age 30.

Comorbidities: depression (>50%), anxiety, PTSD, personality disorders, substance use.

Childhood ACEs and trauma strongly associated with adult SSD.

Functional neurologic disorder (conversion): positive rule-in signs (Hoover, tremor entrainment).

Factitious disorder: intentional + sick role; malingering: intentional + external gain (not a mental illness).

Munchausen by proxy = factitious disorder imposed on another = child abuse → mandatory report.

Pseudocyesis: false belief of pregnancy with physical signs — categorized under "other specified somatic symptom disorder."

Body dysmorphic disorder = OCD-spectrum, not somatoform.

Don't repeat negative workups; do address comorbid mental illness.

Most common symptoms in SSD: pain (back, head, abdominal, joint), GI, sexual, pseudoneurologic.

Functional GI disorders (IBS, functional dyspepsia) frequently overlap.

Fibromyalgia overlaps significantly with SSD with predominant pain.

La belle indifférence classically described in conversion — not specific or required.

CBT response rates in IAD: 60–80% improvement.

SSRIs allow 6–8 weeks before efficacy assessment.

Citalopram max 40 mg (20 mg in elderly) — QT prolongation.

Paroxetine — avoid in pregnancy and elderly.

Duloxetine — avoid in CrCl <30 and hepatic disease.

Board pearl: When in doubt on Step 3, choose scheduled follow-up + CBT referral + SSRI over any test, procedure, or specialist referral in stable somatoform patients.

Board Question Stem Patterns

— 35-year-old woman with 5 years of abdominal pain, headaches, fatigue, dizziness, multiple negative workups across multiple providers. Demands more tests. Answer: establish single PCP with scheduled visits + CBT referral; do not order more imaging.

— 28-year-old man convinced he has ALS after reading online; checks muscles daily; normal neuro exam and EMG. Answer: illness anxiety disorder; treat with CBT + SSRI; address reassurance-seeking behavior.

— Patient intentionally injects insulin to induce hypoglycemia and gain hospital admissions. Answer: factitious disorder (sick role, no external gain).

— Patient claims back pain to obtain opioids and disability. Answer: malingering (external gain).

— Recurrent admissions with confusing presentations; child improves in hospital without mother. Answer: factitious disorder imposed on another; mandatory CPS report.

— Moderate symptoms on sertraline. Answer: continue sertraline; emphasize CBT; avoid paroxetine and benzodiazepines.

— Known SSD, now with weight loss and night sweats. Answer: work up the new symptoms — don't anchor on prior diagnosis.

— Sudden monocular blindness with normal pupils and normal OCT/MRI; tubular visual fields. Answer: functional neurologic disorder; diagnosed by positive findings of incompatibility; treat with PT/CBT.

— Frequent ED visits for chest pain, all negative. Answer: care plan in chart, deprescribe opioids, PCP follow-up within 1–2 weeks; avoid repeat imaging.

— SSD with predominant chronic pain + depression. Answer: duloxetine (treats both).

— Patient says "you think it's all in my head." Best response: validate ("your symptoms are real"), explain mind-body connection, partner on functional goals; do not say "the tests are normal so you're fine."

Pattern 1 — Classic SSD vignette:

Pattern 2 — IAD vignette:

Pattern 3 — Differential trap:

Pattern 4 — Mother induces illness in child:

Pattern 5 — Pregnant patient with somatic disorder:

Pattern 6 — Elderly with new symptom:

Pattern 7 — Conversion/FND:

Pattern 8 — ED management:

Pattern 9 — Choosing pharmacotherapy:

Pattern 10 — Communication question:

Board pearl: In any somatoform stem, distrust answers that say "order another test," "admit for observation," or "prescribe an opioid/benzodiazepine" — they are almost always wrong.

One-Line Recap

— Diagnose: SSD = many symptoms + excessive response; IAD = fear of disease with minimal symptoms; both ≥6 months; comorbid depression/anxiety in >50%.

— Treat: First-line CBT + SSRI (sertraline, fluoxetine, escitalopram; duloxetine if pain predominant); avoid opioids, benzodiazepines, and polypharmacy.

— Structure care: One PCP, scheduled visits every 4–6 weeks, focused exams, function-based goals, no PRN testing, age-appropriate preventive care, and explicit care plans across transitions.

— SSD vs. IAD: symptom-focused vs. diagnosis-focused.

— Factitious (sick role) vs. malingering (external gain) vs. somatoform (unintentional).

— FND is diagnosed by positive incompatibility signs, not exclusion.

— Anchoring bias is the chief patient-safety threat — new objective findings always warrant fresh workup.

Somatic symptom disorder and illness anxiety disorder are chronic conditions of disproportionate distress about bodily symptoms or feared illness that are best managed by a single primary care provider through regularly scheduled visits, CBT, and SSRIs, while resisting the iatrogenic harms of over-testing and over-prescribing.

Three-bullet recap:

High-yield distinctions:

Step 3 management mantra: "One doctor, scheduled visits, CBT, SSRI, no opioids or benzos, function over cure."

Board pearl: When the stem describes a high-utilizer patient with negative prior workup demanding more tests, the answer is almost always regular scheduled follow-up with a single primary care provider plus CBT referral — not another scan, specialist, or pill.